Wegovy for Weight Loss: Complete Treatment Guide and What to Expect

What Wegovy Is and How It Works

Wegovy is a prescription weight loss medication approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with comorbid conditions. The active ingredient is semaglutide, a GLP-1 receptor agonist that mimics the gut hormone glucagon-like peptide 1.

Three mechanisms explain almost all of the weight loss benefit. Semaglutide slows gastric emptying so meals stay satisfying for longer. It quiets the brain signals that drive food noise (the constant low-level thoughts about eating). And it improves post-meal blood sugar regulation, which reduces the energy crashes that trigger cravings. The clinical result is a substantial drop in daily calorie intake without the willpower fatigue that wrecks most diet attempts. For a related GLP-1 option, see our guide on how Zepbound works for weight loss.

Wegovy is designed to work alongside a reduced-calorie diet and regular physical activity. It’s a tool, not a replacement for the basics. The dose climbs gradually over 16 to 20 weeks because that titration schedule is what makes the gastrointestinal side effects tolerable.

The evidence base is strong. In the landmark trial “Once-Weekly Semaglutide in Adults with Overweight or Obesity,” published in the New England Journal of Medicine in 2021 by Wilding and colleagues (the STEP 1 trial, 1,961 adults without diabetes), participants on semaglutide 2.4 mg lost a mean of 14.9 percent of body weight at 68 weeks versus 2.4 percent on placebo, and 86.4 percent reached at least 5 percent weight loss. Benefits may extend well beyond the scale: in the SELECT cardiovascular outcomes trial (“Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes,” Lincoff and colleagues, New England Journal of Medicine, 2023, 17,604 adults with established cardiovascular disease), weekly semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent over a mean 39.8 months. That said, you should discuss your own risk profile with a provider, since trial averages do not predict any single person’s result.

Week 1: What to Expect

The first week of Wegovy is an adjustment phase, not a results phase. Starting dose is 0.25 milligrams of semaglutide weekly, given by a once-weekly subcutaneous injection. Most patients lose 1 to 3 pounds in the first 7 days, though that’s primarily water rather than fat.

Here’s what week 1 typically looks like:

1. Injection: The first dose goes into the abdomen (avoiding the area around the belly button) or upper outer thigh. Most patients describe the pen as nearly painless. Some redness or a small wheal at the injection site is normal.
2. Initial Side Effects: Mild nausea, occasional reflux, and changes in bowel patterns are the most common reactions during days 1 through 4. These usually fade within 3 to 5 days.
3. Appetite Changes: Most patients notice reduced hunger by day 3 or 4. Smaller portions feel satisfying, and afternoon snacking often drops away naturally.
4. Mood and Energy: Mild fatigue is common as the body adjusts. Pair Wegovy with adequate hydration, protein, and sleep to dampen this.

Side Effects in the First Week

Common first-week side effects include:

• Nausea: Reported by roughly 44 percent of patients in clinical trials. Smaller, blander meals and ginger tea help. Avoid heavy or fatty foods for 24 to 48 hours after each injection.
• Vomiting: Less common. If it becomes persistent, contact your provider.
• Diarrhea or constipation: Typically transient. Add 25 to 35 grams of fiber daily and an extra 16 to 24 ounces of water.
• Reduced appetite: The intended effect. Make sure you’re still hitting protein targets (0.7 to 1 gram per pound of goal weight) so muscle is preserved.

Side effects are generally mild to moderate and often decrease as the body adjusts. For severe or persistent symptoms, our side effect timeline guide walks through duration and management strategies.

How to Administer Wegovy

Wegovy comes as a single-use pen. The injection takes about 10 seconds once you’re set up, and you’ll be trained on technique at your first visit. Here’s the sequence:

Most patients pick a regular weekly day (Saturday morning is common) so the post-injection window falls on a weekend rather than a workday. Stay consistent: dose timing should not vary by more than 48 hours week to week.

Weeks 2 to 4: Settling In

Weeks 2 through 4 are still on the 0.25 milligram starting dose. Side effects are typically milder than week 1. Most patients lose another 1 to 3 pounds during this stretch, with continued reduction in appetite and food cravings.

This is the period to lock in the basics. Aim for 0.7 to 1 gram of protein per pound of goal body weight daily, 25 to 35 grams of fiber, and at least 64 ounces of water. Add resistance training 2 to 3 times per week if you’re not already strength training. The faster you build the habit foundation, the better long-term results will be.

Months 2 to 3: Building Momentum

Dose climbs to 0.5 milligrams at week 5 and 1 milligram at week 9. Appetite suppression becomes more pronounced, and many patients hit a comfortable rhythm of 2 small meals plus a protein-rich snack daily. Weight loss accelerates: average loss reaches 6 to 12 percent of starting body weight by the end of month 3.

Each dose increase brings a brief recurrence of the early side effects (mild nausea, fatigue) for 2 to 4 days, then settles. If side effects don’t settle within a week, your provider may pause titration to give your body more time. There’s no medal for climbing fast.

Mood often improves during this period as visible progress builds confidence. Energy is usually steady if protein and B vitamins are adequate. If fatigue is persistent, our liquid B12 guide covers when supplementation makes sense.

Appetite Changes and Emotional Shifts

One of the defining features of Wegovy treatment is the change in food noise. Patients describe a quieter relationship with food: cravings become less frequent, smaller portions feel satisfying, and many of the foods that used to be hard to resist lose their pull. The shift typically becomes obvious between weeks 4 and 8.

Some emotional effects show up alongside the physical ones. Mild mood swings and fatigue early in treatment are common as the body adjusts to hormonal signaling changes. These usually settle by month 2. If they persist or worsen, a conversation with your provider is appropriate, particularly if mood changes are significant. Our medical weight loss program includes regular check-ins to catch issues early.

Months 4 to 6: Reaching the Therapeutic Dose

Dose climbs to 1.7 milligrams at week 13, then 2.4 milligrams at week 17. By this point, food noise has quieted significantly and most patients report they’re eating differently rather than fighting hunger. Weight loss averages 11 to 15 percent of starting body weight by month 6.

Lab work at this stage is worth reviewing: thyroid panel, fasting glucose and HbA1c, lipids, B12, vitamin D, iron, and electrolytes. Many patients see substantial improvements in metabolic markers (HbA1c, blood pressure, triglycerides) regardless of total weight lost. Some see improvements in joint pain and sleep quality first, weight on the scale second.

Two practical issues become important now. First, hydration: GLP-1 medications dampen thirst signals slightly, and dehydration drives fatigue and headaches. Second, lean mass: at 1.7 milligrams and above, food intake can drop sharply. Hitting protein targets and continuing strength training matters more than ever.

Month 6 and Beyond: Maintenance

Most patients continue at 2.4 milligrams weekly through month 12, when the full clinical trial endpoints are typically reached. Average total weight loss in the STEP 1 trial (Wilding and colleagues, New England Journal of Medicine, 2021) was 14.9 percent of starting body weight at 68 weeks, with most of the loss occurring in the first 60 weeks before the trajectory leveled off. Continued treatment can protect that result: in the STEP 4 trial (Rubino and colleagues, JAMA, 2021, 803 adults randomized after a 20-week run-in), people who kept taking semaglutide lost a further 7.9 percent over the next 48 weeks, while those switched to placebo regained 6.9 percent.

Three patterns are common at maintenance:

• Continue at 2.4 milligrams indefinitely: Many patients stay on full-dose Wegovy long term. Trial data through 2 years shows continued maintenance of weight loss with stable side effect profile.
• Drop to a lower maintenance dose: Some patients move from 2.4 to 1.7 or 1 milligram weekly once they’ve reached their goal. The lower dose is enough to preserve appetite changes for many people.
• Plan a structured taper off: A small subset transitions off the medication entirely with a defined nutrition and exercise plan. Expect partial regain (in the STEP 4 trial, people switched to placebo regained about 6.9 percent of body weight over the 48 weeks after stopping) and prepare accordingly.

None of the three is the universally right choice. The right answer depends on your goals, your medical history, your insurance, and your relationship with food at the maintenance point.

Handling a Plateau

Plateaus on Wegovy are normal. Weight loss is rarely linear, and most patients hit a flat stretch somewhere between months 3 and 9. The plateau itself isn’t a problem; what matters is what’s driving it.

Common plateau causes, in order of frequency:

1. Calorie creep: Portions gradually grow, snacks reappear, and weekend eating loosens. Track honestly for 7 days to spot it.
2. Lower NEAT: Non-exercise activity (steps, fidgeting, daily movement) drops as your body conserves energy. Add 2,000 daily steps before adjusting anything else.
3. Inadequate protein: Lean mass loss slows metabolism. Hit your protein target every day.
4. Hormonal shifts: Thyroid, cortisol, or sex hormone changes can stall progress. Lab work and our hormone optimization program can identify and address these.
5. Body recomposition: If you’re strength training hard, you may be losing fat and gaining muscle simultaneously. Photos and waist measurements often reveal the truth the scale hides.

If a plateau lasts beyond 6 weeks despite addressing the basics, options include increasing the dose if you’re below 2.4 milligrams, switching to tirzepatide (which works on both GLP-1 and GIP receptors), or pausing Wegovy temporarily for 4 to 6 weeks. Our guide to GLP-1 plateaus has a full troubleshooting walkthrough.

Stopping or Transitioning Off Wegovy

Stopping Wegovy is a planned event, not a casual decision. Once the medication is out of the system, appetite returns to baseline, food noise comes back, and weight regain is common without a structured plan in place.

The realistic options are:

• Indefinite maintenance dosing: Stay on a lower weekly dose (1 to 1.7 milligrams) for ongoing appetite control.
• Structured taper with maintenance plan: Reduce dose stepwise over 8 to 12 weeks while locking in nutrition habits, strength training, and weekly weigh-ins. Most successful tapers happen for patients already eating and moving like the version of themselves they want to maintain.
• Switch to a different tool: Some patients move from semaglutide to a different GLP-1 medication (like tirzepatide) or pair it with B12, peptide therapy, or a metabolic support protocol. Our peptide therapy program and IV therapy are options patients sometimes use during transition.

Monitoring Your Progress

Tracking the right metrics matters more than tracking everything. Weight on the scale is noisy day to day; it’s most useful as a weekly average. The metrics that actually show whether treatment is working:

• 7-day average body weight, weighed at the same time of day under similar conditions
• Waist circumference at the navel, measured monthly
• Photos in consistent lighting taken every 4 to 6 weeks (front, side, back)
• Lab work every 3 months: HbA1c, fasting glucose, lipid panel, B12, vitamin D, electrolytes, comprehensive metabolic panel
• Strength benchmarks if you’re training: how much you lift in 2 to 3 main movements
• Subjective wellbeing: energy, sleep, mood, food noise rating on a 0 to 10 scale

Bring this data to your follow-up visits. It’s the difference between “we’ll keep going” and a precise dose adjustment, additional supplementation, or a switch to a different protocol.

When to Contact Your Healthcare Provider

Contact your provider promptly if you experience:

• Severe or persistent nausea, vomiting, or diarrhea that prevents fluid intake
• Severe abdominal pain (possible pancreatitis)
• Right-upper-quadrant pain radiating to the back or shoulder (possible gallbladder issue)
• Difficulty breathing or facial, lip, or throat swelling (allergic reaction)
• Sudden vision changes
• Symptoms of severe dehydration: dizziness on standing, dark urine, dry mouth
• Persistent fatigue or low mood that doesn’t respond to adequate protein, B12, and sleep

For non-urgent issues such as ongoing mild nausea, schedule your next follow-up rather than waiting until the next planned visit. Our team adjusts dosing, timing, or supportive care based on what you’re experiencing in real time.

Frequently Asked Questions

Related Articles